Research advances are finally translating to companies, as a spate of new startups works to translate laboratory discoveries into commercialization opportunities anchored on successful new gene therapies. "We are indeed in a biotech bubble where investment in biotech in general has escalated/' said James M. Wilson, MD, PhD, director of the gene therapy program at the University of Pennsylvania and scientific founder of REGENX, which licenses the next generation of adeno-associated virus (NAV?) vector technology he discovered at his University of Pennsylvania laboratory.
展开▼
